Abstract：Objective To investigate the clinical significance of βisomer of C-terminal telopeptide (β-CTX) in Zoledronic acid (ZOL) combined with chemotherapy for non-small cell lung cancer (NSCLC) with bone metastasis. MethodsNewly diagnosed NSCLC patients with bone metastasis (n=60) were randomised to the test group (n=30), who received ZOL combined with chemotherapy, or a control group (n=30), who received chemotherapy alone. Serum β-CTX was measured by ELISA before and after treatment in two groups. ResultsThe total effective rate was 90.00% in the treatment group were higher than that of the control group (63.33%) (P<0.05). The level of β-CTX after treatment in treatment group was lower than that before treatment (P<0.05), while in control group had no significant difference (P>0.05). ConclusionZOL administered with chemotherapy can more effectively reduce β-CTX levels for NSCLC patients with bone metastasis. Indicating that the change of β-CTX might be as a valuable index to ZOL for the treatment of NSCLC patients with bone metastasis.
潘兴喜，杨文，陈永发. 唑来膦酸联合化疗治疗非小细胞肺癌骨转移前后血清 β-CTX 水平的变化[J]. 肿瘤代谢与营养电子杂志, 2017, 4(4): 441-444.
PAN Xing-xi, YANG Wen, CHEN Yong-fa. Changes of serum β-CTX levels in non-small cell lung cancer with bone metastasis after treated by Zoledronic acid combined with chemotherapy. Electronic Journal of Metabolism and Nutrition of, 2017, 4(4): 441-444.
